1. BioSafety Considerations For Viral Vectors

2. Biosafety Considerations of Viral Vectors n Lifestyles of the Small & Infectious n Terminology of Gene Expression n Viruses to Vectors n Vectors and More Vectors

3. Lifestyles of the Small and Infectious Very Basic Virology

5. What Are Viruses? n Small, infectious obgligate intracellular parasites whose genome is either DNA or RNA. n The viral genome is replicated within a host cell and uses cellular systems to direct the synthesis of other virion components. n These newly synthesized components are used to assemble progeny virions which are responsible for transmission of the viral genome to the next host cell.

7. Common Viral Strategies n All viruses package their genome inside a particle that mediates transmission of the viral genome from host to host. n The viral genome contains the information for initiating and completing an infectious cycle. n All viruses are able to establish themselves in a host population.

9. Terminology of Gene Expression What is…???

10. n cDNA : a DNA copy of an mRNA –Only contains the protein coding domain (not introns) –When transcribed the RNA requires no processing –Can be translated directly n Transgene –A gene that is put into some sort of expression vector to be delivered into a cell

11. Expression Cassette n Piece of DNA that contains all the elements necessary for a gene to be expressed in a cell.

12. Elements of an Expression Vector Promoters are tailored to type of cell system: bacteria, mammalian, insect, etc. Termination signals are tailored to prokaryotic or eukaryotic systems: eukaryotic cells require polyA signal.

13. Cis & Trans Acting Elements n Cis – present on the same piece of DNA/RNA being acted on; cannot function separately. –Promoters, signaling sites n Trans – elements that act on a different piece of DNA/RNA than the one they are present on. –Viral replication proteins, RNA polymerase

14. Complementing Cell Lines n Complementation: Providing trans-acting functions to rescue a nucleic acid that is missing, or mutant in, those functions. n By stably transfecting cells to express a gene product necessary for viral replication, can then grow viruses deleted for that gene. –HEK293 cells express Ad E1; will complement E1 deleted adenoviruses.

15. Viruses to Vectors Biosafety Considerations

16. Why Use Viruses? n Viruses have evolved to efficiently condense, package, & deliver nucleic acids to cells. n Relatively easy to generate & renew. n Infect a wide variety of cell types. n Production of proteins w/ authentic post translational modifications. n Potential for regulated production. n Potential for in vivo gene delivery.

17. Concerns About Recombinant Viruses n Pathogenicity of parental virus. –Can engineer to be repl. incompetant n Cytopathogenicity of vector. –eg. Spike proteins on Adenovirus n Requirements for specialized facilities. n Scale-up considerations. n Training requirements.

18. Replication Incompetent Viruses n To avoid potential pathogenicity of viral vectors – disable them so they cannot replicate in target cells. n Usually accomplished by deleting genes that provide necessary trans-acting functions from the vector genome. n Introduction of genes & defective vector into cells results in synthesis of vector genomes & packaging of the defective genomes into virus particles.

19. Reconstitution of Replication Competent Virus (RCV) n During amplification & packaging of defective viral vector genomes they can, at low frequency, re-acquire the genes necessary for autonomous growth, making the virus replication competent again. n Occurs by recombination.

20. Strategies to Avoid RCV Reconstitution n Split genomes: putting replication genes on different DNA constructs n Remove viral regulatory regions n Produce as a transient single batch rather than continuous culture n Use non-host cell lines – reduces “rescue”

21. Why Do Split Genomes Decrease RCV Risk?

22. Pseudotyping of Viruses n The use of different viral surface proteins to affect the host range of the virus and/or to change physical properties of the viral particles. n Some viruses are surrounded by cell-derived membranes & foreign surface proteins can be included in these envelopes. –G glycoprotein of vesticular stomatitis virus –Eliminates ability to regenerate original host range

24. Vectors …and more Vectors

25. Typical Viruses Used n Retrovirus/Lentivirus n Adenovirus n Baculovirus (insect cells) n Poxvirus (vaccinia, fowlpox) n Herpesvirus n Alpha virus (SFV, sindbis, VEE) n Adeno-Associated Virus

26. Common Viral Vectors

27. Retroviruses n Based on murine leukemia virus –Risk Group 1 and 2 n Simple genomic structure: all the retroviral genes can be removed & supplied extraneously –Three genes: gag, pol, env

28. Biosafety Concerns n Amphotropic viruses are capable of infecting human cells, therefore biosafety concern is on effects of the expressed gene n Replication competent retroviral breakthroughs

29. Lentiviruses n Complex retrovirus, based on HIV genome

30. Lentivirus n Capable of infecting non-dividing cells –Provirus DNA must enter nucleus for integration of DNA to occur –Simple retroviruses rely on dissolution of nuclear membrane during mitosis –Lentiviruses encode nuclear localization signals which transport complex into nucleus

31. Biosafety Concerns for Lentivirus n Generation of replication competent virus n Infection of non-target cells n Inappropriate expression of gene product in non-intended cell type n Insertional mutagenesis n “Rescue” by other human pathogenic viruses

32. Insertional Mutagenegis n Lentivirus integrates into the host chromosome at random. n Possible to integrate in area such that downstream LTR could function as a promoter for growth regulation.

33. “Rescue” n Host genome may contain endogenous retrovirus n Recombination event could lead to reactivation or “rescue” of replication competent virus

34. How Is Safety Engineered Into Lentiviral Vectors? n Lentivirus- 3rd generation Lentivirus System. Significantly modified for biosafety. –Packaging vector lacks both LTRs and expresses only gag and pol. –Rev is supplied in trans on a separate vector. –The vector expressing the packaged viral genome has a self-inactivating LTR and expresses no viral gene products –The envelope protein is VSV-G and is also expressed on a separate vector –Packaged virus expresses no viral gene products

35. Adenoviruses n Risk Group 2 n Deletions of the E1 region render the virus replication incompetent; can be propagated in a complementing cell line (293 cells) n Airborne Transmitted; infects broad range of cells

36. Adenovirus Vector Advantages n High titers n Infects wide ranges of cells n Infects dividing and quiescent cells n Virion stability Disadvantages n Have had some adverse events n Transient expression n Problems w/ subsequent administration in gene therapy n Based on human pathogen n RCA breakthroughs

37. Baculovirus n Risk group 1 agent n Enveloped virus w. double stranded DNA genome n Insect pathogen that does not propagate in mammalian cells n Used for many years to express proteins; will also deliver genes and mediate expression in mammalian cells

38. Baculoviruses as Gene Delivery Vehicles for Mammalian Cells n Virus will deliver its DNA into mammalian cells n Viral promoters are not activated in mammalian cells but if expression cassette is included with a mammalian promoter, it will be expressed n No overt deleterious effects on mammalian cells have been shown

39. Baculovirus Vectors Advantages n Ease of Use n Broad host range n Efficiency & lack of toxicity n Non-replicative in mammalian cells n Inactivated by human complement Limitations n Relatively uncharacterized n Potential for maintenance of viral DNA n No evidence of in vivo delivery n Potential expression of viral gene products

40. Vaccinia Virus n Risk Group 2 n Enveloped virus w/ double stranded DNA genome n Extensive use as recombinant protein expression vector n Wide host range n Clone large DNA fragments (> 20 Kb) n Used as a live vaccine against smallpox

41. Vaccina Virus Vector Advantages n Broad host range n Easy to generate viruses n Accepts large inserts n High expression level n Molecular virology well understood Limitations n Lytic infections n Readily transmisible agent n Vaccination requirement n Scale-up considerations

42. Avipox Vectors n Poxviral vectors are replication competent n Poxviruses that infect avian species (fowlpox and canarypox) are replication defective in mammalian cells n Vectors based on these viruses might provide a safer alternative to vaccinia based vectors for in vivo use

43. Alpha Viruses n Risk Group 2 and 3 agents n Enveloped virus w/ single stranded RNA genome n Arthropod-borne viruses; replicate in cells from vertebrates & invertebrates n Consequence of human alphavirus infection can be mild or significant disease. n Main in vivo application is to expression of antigen to elicit an immune response

44. Recombinant Alphaviruses n Vector systems have been developed from three alpha viruses: –Sindbis virus (SIN, risk group 2); –Semliki Forest Virus (SFV, risk group 2/3); –Venezuelan Equine Encephalitis (VEE, risk group 3) n SIN and SFV systems are commercially available

45. Alphaviral Vectors Advantages n High expression level n Broad host range n High titers n Ease of use Limitations n Cytopathic n Replication competent virus n Based on human pathogen n Large Scale production

46. Herpes Virus n Risk Group 2 n HSV1 & HSV2: Enveloped virus w/ double stranded DNA genome n Replicates in the nucleus n Dual life cycle: lytic growth in epithelial cells; latent infection in neuronal cells

47. Herpesviral Vectors Advantages n Accepts large inserts n Broad host range n High titer n Latency in neuronal cells persistence of expression Disadvantages n Virus spread by direct contact n Complex, extensive engineering of vectors n Latency not well- understood

48. Adeno-Associated Virus (AAV) n Risk group 1 agent n Human parvovirus-not associated with any disease n Majority of population is seropositive n Requires a helper virus (adeno or herpes coinfection for replication) n AAV integrates into the host cell chromosome (19) n Lack of initiation of immune response

49. AVV Vectors Advantages n Infects multiple cell types n No viral genes in vector n Long term gene expression (persistence of genome) n No immune response Limitations n Limited insert size n Helper virus contamination n Large Scale production n Genome persistence not understood

50. Emerging Vectors n Simian Virus 40 n Rhabdovirus n Influenza Virus n Poliovirus n Hepatis B Virus n Epstein Barr Virus n Parvovirus n Chimeric viruses –Adeno-retroviral –Adeno-AAV –Alpha-retroviral –Alpha-rhabdoviral

51. Challenges of Risk Assessment n A= viral vector system n B= expression construct n Quite often…A + B = A* n But sometimes…A + B = C n Need realistic risk assessment for –Protection of personnel –Guidance for containment & work practices

52. Thanks To: n Patrick Condreay, PhD –GloxoSmithKline Discovery Research n Flint, Enquist, Krug, Racaniello, Skalaka –Authors: Principles of Virology n Bristol-Myers Squibb Central NJ IBC